Bausch + Lomb Co. (NYSE:BLCO) Receives $19.83 Consensus Price Target from Brokerages

Bausch + Lomb Co. (NYSE:BLCO) has received an average recommendation of “Hold” from the twelve brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $20.00.

A number of analysts have weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, February 20th. Wells Fargo & Company reduced their price target on shares of Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, January 16th. Royal Bank of Canada lowered their price objective on Bausch + Lomb from $22.00 to $18.00 and set an “outperform” rating on the stock in a research report on Thursday, February 20th. Citigroup cut Bausch + Lomb from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $24.00 to $22.00 in a research note on Wednesday, December 11th. Finally, Bank of America lowered their price target on Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating on the stock in a report on Thursday, February 20th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BLCO. Blue Trust Inc. increased its position in shares of Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock valued at $48,000 after purchasing an additional 1,004 shares during the last quarter. State Street Corp grew its position in Bausch + Lomb by 5.6% during the third quarter. State Street Corp now owns 28,450 shares of the company’s stock valued at $549,000 after buying an additional 1,510 shares during the period. HighTower Advisors LLC increased its holdings in Bausch + Lomb by 14.7% during the third quarter. HighTower Advisors LLC now owns 24,661 shares of the company’s stock valued at $476,000 after buying an additional 3,164 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Bausch + Lomb in the fourth quarter worth approximately $72,000. Finally, XTX Topco Ltd boosted its stake in shares of Bausch + Lomb by 25.4% during the 4th quarter. XTX Topco Ltd now owns 20,077 shares of the company’s stock worth $363,000 after acquiring an additional 4,065 shares during the last quarter. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Stock Performance

Bausch + Lomb stock opened at $16.00 on Monday. Bausch + Lomb has a twelve month low of $13.16 and a twelve month high of $21.69. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $5.64 billion, a P/E ratio of -17.58, a PEG ratio of 0.85 and a beta of 0.46. The stock’s 50 day moving average is $17.12 and its 200 day moving average is $18.14.

Bausch + Lomb (NYSE:BLCO) last released its earnings results on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.24 earnings per share. On average, equities research analysts predict that Bausch + Lomb will post 0.74 earnings per share for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.